Status:
COMPLETED
Can we Better Understand the Development of VAP and Eventually Predict and Prevent it?
Lead Sponsor:
University Hospital, Geneva
Conditions:
Pneumonia, Ventilator-Associated
Eligibility:
All Genders
18+ years
Brief Summary
Pathogens of ventilator-associated pneumonia (VAP) come from colonizers of the trachea. The hypothesis of the investigators is that during the first days of intubation, independently of the use of ant...
Detailed Description
BACKGROUND OF THE STUDY: The ventilator-associated pneumonia (VAP) is responsible for almost half of infections acquired in intensive care, affecting up to 28% of mechanically ventilated patients wit...
Eligibility Criteria
Inclusion
- Patient hospitalised in the adult ICU of HUG (\>18 years old)
- Intubated for \< 24 hours
- Expected duration of intubation \> 4 days (e.g. neurologic disease)
Exclusion
- Patients for whom regular tracheal aspirations cannot not be performed (because of unstable intracranial pressure, for example).
- New antibiotic therapy in the week preceding the intubation
Key Trial Info
Start Date :
October 1 2012
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 1 2014
Estimated Enrollment :
286 Patients enrolled
Trial Details
Trial ID
NCT01875692
Start Date
October 1 2012
End Date
March 1 2014
Last Update
December 3 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospital
Geneva, Canton of Geneva, Switzerland, 1201